Last reviewed · How we verify

BPGbio — Portfolio Competitive Intelligence Brief

BPGbio pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Addpharma Inc. · 1 shared drug class
  2. Aevi Genomic Medicine, LLC, a Cerecor company · 1 shared drug class
  3. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  4. Amorphical Ltd. · 1 shared drug class
  5. Angitia Incorporated Limited · 1 shared drug class
  6. Applied Biology, Inc. · 1 shared drug class
  7. Aptarion Biotech AG · 1 shared drug class
  8. AB Science · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BPGbio:

Cite this brief

Drug Landscape (2026). BPGbio — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bpgbio. Accessed 2026-05-14.

Related